Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on ProMIS Neurosciences. The associated price target remains the same with $3.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason McCarthy has given his Buy rating due to a combination of factors that highlight the potential of ProMIS Neurosciences’ PMN310 in treating Alzheimer’s disease. The company’s ongoing Phase 1b study has shown promising safety results, with no cases of amyloid-related imaging abnormalities (ARIA), a common risk in amyloid treatments. This is significant as PMN310 targets amyloid-beta oligomers instead of plaques, potentially reducing ARIA risk.
Moreover, the study’s progress, including the approval to proceed to the final dose cohort, suggests a positive trajectory for future data releases. Interim data expected in the second quarter of 2026 and final results in the fourth quarter of 2026 could further validate PMN310’s efficacy. Additionally, the valuation model incorporates a 70% revenue risk adjustment and a 30% discount rate, leading to a 12-month price target of $3.00, which supports the Buy rating.
According to TipRanks, McCarthy is an analyst with an average return of -19.1% and a 32.40% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as OS Therapies Incorporated, Capricor Therapeutics, and Brainstorm Cell Therapeutics.